Covid Apollo Project Makes Investment in Rhinostics to Accelerate Covid-19 Testing Volumes Through High Throughput Sample Accessioning

12 Mar, 2021

Covid Apollo Project Makes Investment in Rhinostics to Accelerate Covid-19 Testing Volumes Through High Throughput Sample Accessioning
Photo by Wesson Wang on Unsplash

– Covid Apollo announces its investment in Rhinostics, an early-stage company that provides a novel solution of enabling comfortable sample collection, rapid accessioning, and automated cap removal that can be linked to high throughput Covid-19 assays to remove wasted time, headcount and costs from laboratory workflows.
– The Covid Apollo Project brings together expertise and capital to find and help scale the most promising Covid-19 diagnostic opportunities.
– Originally funded under the leadership of RA Capital Management, the Project includes Redmile Group, Samsara BioCapital, Perceptive Advisors, and Bain Capital.
– Covid Apollo is focused on finding and accelerating the most promising COVID testing solutions to rebuild testing paradigms to address the unique challenges that the pandemic has presented.

Medical Device North America
Crunchbase icon

Content report

The following text will be sent to our editors: